Belite Bio Reports Q3 Non-GAAP EPS of -$0.60, Exceeding Estimates
Belite Bio (BLTE) reported third-quarter non-GAAP earnings per share (EPS) of -$0.60, which outperformed analyst expectations by $0.17. The results indicate a narrower-than-anticipated loss for the period. Regarding its liquidity position, the company held $271.3 million in cash and cash equivalents as of September 30, 2026. This represents a decrease from the $352.9 million reported at the end of December 2025.
Tickers: $BLTE
Topics: cash position earnings beat non-GAAP EPS